Our suggestion would be best to carry out the anti-AD research of DPP-4i after a breakthrough in the anti-AD research of GLP-1/GLP-1R or the combination of DP-4i and the first approved effective anti-AD drug. Here, GLP1R is linked to Alzheimer disease.